ZA201700488B - Method for positioning, in cytoplasm, antibody having complete immunoglobulin form by penetrating antibody through cell membrane, and use for same - Google Patents
Method for positioning, in cytoplasm, antibody having complete immunoglobulin form by penetrating antibody through cell membrane, and use for sameInfo
- Publication number
- ZA201700488B ZA201700488B ZA2017/00488A ZA201700488A ZA201700488B ZA 201700488 B ZA201700488 B ZA 201700488B ZA 2017/00488 A ZA2017/00488 A ZA 2017/00488A ZA 201700488 A ZA201700488 A ZA 201700488A ZA 201700488 B ZA201700488 B ZA 201700488B
- Authority
- ZA
- South Africa
- Prior art keywords
- antibody
- cytoplasm
- positioning
- same
- cell membrane
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/32—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/46—Hybrid immunoglobulins
-
- G01N33/575—
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/515—Complete light chain, i.e. VL + CL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/77—Internalization into the cell
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/80—Immunoglobulins specific features remaining in the (producing) cell, i.e. intracellular antibodies or intrabodies
- C07K2317/82—Immunoglobulins specific features remaining in the (producing) cell, i.e. intracellular antibodies or intrabodies functional in the cytoplasm, the inner aspect of the cell membrane, the nucleus or the mitochondria
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Oncology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Cell Biology (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Biomedical Technology (AREA)
- Hospice & Palliative Care (AREA)
- Biotechnology (AREA)
- Medicinal Preparation (AREA)
- Food Science & Technology (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR20140092673 | 2014-07-22 | ||
| KR1020150103163A KR101602870B1 (ko) | 2014-07-22 | 2015-07-21 | 완전한 이뮤노글로불린 형태의 항체를 세포막을 투과하여 세포질에 위치시키는 방법 및 그의 이용 |
| PCT/KR2015/007626 WO2016013870A1 (ko) | 2014-07-22 | 2015-07-22 | 완전한 이뮤노글로불린 형태의 항체를 세포막을 투과하여 세포질에 위치시키는 방법 및 그의 이용 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ZA201700488B true ZA201700488B (en) | 2018-12-19 |
Family
ID=55354088
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ZA2017/00488A ZA201700488B (en) | 2014-07-22 | 2017-01-20 | Method for positioning, in cytoplasm, antibody having complete immunoglobulin form by penetrating antibody through cell membrane, and use for same |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US10844136B2 (enExample) |
| EP (1) | EP3173428B1 (enExample) |
| JP (1) | JP6595592B2 (enExample) |
| KR (1) | KR101602870B1 (enExample) |
| CN (1) | CN107001481A (enExample) |
| AU (1) | AU2015292955B2 (enExample) |
| BR (1) | BR112017001304A2 (enExample) |
| CA (1) | CA2955272A1 (enExample) |
| IL (1) | IL250203B (enExample) |
| RU (1) | RU2017103675A (enExample) |
| ZA (1) | ZA201700488B (enExample) |
Families Citing this family (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2694555B1 (en) | 2011-04-01 | 2019-07-10 | Yale University | Cell-penetrating anti-dna antibodies and uses thereof to inhibit dna repair |
| KR101602870B1 (ko) | 2014-07-22 | 2016-03-21 | 아주대학교산학협력단 | 완전한 이뮤노글로불린 형태의 항체를 세포막을 투과하여 세포질에 위치시키는 방법 및 그의 이용 |
| KR101602876B1 (ko) | 2014-07-22 | 2016-03-11 | 아주대학교산학협력단 | 완전한 이뮤노글로불린 형태의 세포질 침투능을 갖는 항체를 이용하여 세포내 활성화된 ras를 억제하는 방법 및 그의 이용 |
| US11155641B2 (en) | 2016-05-27 | 2021-10-26 | Orum Therapeutics Inc. | Cytosol-penetrating antibody and use thereof |
| KR102000000B1 (ko) * | 2016-05-27 | 2019-07-12 | 오름테라퓨틱 주식회사 | 항체에 엔도좀 탈출능을 부여하는 엔도좀 탈출 구조 모티프 및 이의 활용 |
| US12486318B2 (en) | 2016-06-15 | 2025-12-02 | Yale University | Anti-guanosine antibody as a molecular delivery vehicle |
| JP2019518040A (ja) | 2016-06-15 | 2019-06-27 | イェール ユニバーシティーＹａｌｅ Ｕｎｉｖｅｒｓｉｔｙ | 腫瘍に対して標的化されるナノキャリアの抗体媒介性自触反応的送達 |
| KR102163305B1 (ko) | 2017-11-16 | 2020-10-08 | 오름테라퓨틱 주식회사 | 세포의 세포질에 침투하여 세포내 활성화된 Ras를 억제하는 항체 및 이의 용도 |
| US12304970B2 (en) | 2018-02-01 | 2025-05-20 | Yale University | Nuclear localization signals, compositions formed therefrom, and methods of use thereof for delivery of cargo to the nucleus |
| US20210030850A1 (en) * | 2018-04-10 | 2021-02-04 | Northwestern University | Extracellular vesicles comprising targeting affinity domain-based membrane proteins |
| WO2019244086A1 (en) * | 2018-06-21 | 2019-12-26 | Orum Therapeutics Inc. | Cell/tissue-specific cell-penetrating antibodies |
| WO2020022262A1 (en) * | 2018-07-23 | 2020-01-30 | Chugai Seiyaku Kabushiki Kaisha | Target cell specific cytosol-penetrating antigen-binding molecules |
| CN110759996B (zh) * | 2018-07-27 | 2022-09-06 | 深圳康体生命科技有限公司 | 一种gfp抗体 |
| CN108949565B (zh) * | 2018-09-26 | 2024-09-06 | 中国科学技术大学 | 用于红细胞负载冻干保护剂的装置及方法 |
| ES3042223T3 (en) * | 2019-05-01 | 2025-11-19 | Univ Santiago Compostela | Intracellular delivery of anti-kras antibodies formulated into nanocapsules |
| WO2021158073A1 (ko) | 2020-02-06 | 2021-08-12 | 아주대학교산학협력단 | 항원 유래 t 세포 항원 에피토프 또는 이를 포함하는 펩타이드를 세포 표면에 제시하기 위한 융합항체, 및 이를 포함하는 조성물 |
| IL295788A (en) * | 2020-02-24 | 2022-10-01 | Oblique Therapeutics Ab | epitopes and kras antibodies |
| JP2023519967A (ja) * | 2020-03-30 | 2023-05-15 | アブリンクス・エヌ・フェー | 多価免疫グロブリン単一可変ドメインの製造及び精製のための方法 |
| US20220112308A1 (en) * | 2020-04-30 | 2022-04-14 | Genentech, Inc. | Kras specific antibodies and uses thereof |
| KR102623211B1 (ko) | 2021-07-20 | 2024-01-11 | 아주대학교산학협력단 | 세포 내부에 침투하여 표적단백질을 분해하여 제거하는 세포침투 분해항체 및 이의 용도 |
Family Cites Families (28)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2706486B1 (fr) | 1993-06-16 | 1995-09-01 | Rhone Poulenc Rorer Sa | Séquences nucléiques, vecteurs les contenant, compositions pharmaceutiques et utilisations thérapeutiques. |
| CN1241574A (zh) | 1998-07-02 | 2000-01-19 | 中国人民解放军第四军医大学 | 抗肝癌单克隆抗体HAb25及其单链抗体和双功能抗体 |
| GB0226727D0 (en) | 2002-11-15 | 2002-12-24 | Medical Res Council | Intrabodies |
| WO2003077945A1 (en) | 2002-03-14 | 2003-09-25 | Medical Research Council | Intracellular antibodies |
| CA2506128A1 (en) | 2002-11-15 | 2004-06-03 | Medical Research Council | Anti-activated ras antibodies |
| KR20090008290A (ko) | 2006-03-27 | 2009-01-21 | 글로브이뮨 | Ｒａｓ 돌연변이와 그에 관련된 조성물 및 방법 |
| CN101965406A (zh) | 2008-01-03 | 2011-02-02 | 斯克里普斯研究院 | 通过模块识别结构域的抗体靶向 |
| KR100849941B1 (ko) | 2008-04-29 | 2008-08-01 | 원우이에프엔지니어링주식회사 | 열 및 연기 화재감지장치 복합시험기 |
| EP2279002B1 (en) * | 2008-04-30 | 2013-08-14 | Ajou University Industry-Academic Cooperation Foundation | Anti-nucleic acid antibody inducing cell death of cancer cells and composition for preventing or treating cancers comprising the same |
| KR101075123B1 (ko) * | 2008-10-24 | 2011-10-19 | 아주대학교산학협력단 | 핵산가수분해 능 및 암세포내 침투능력을 갖는 인간화된 항체 및 그 용도 |
| CN102209726A (zh) | 2008-11-11 | 2011-10-05 | 亚州大学校产学协力团 | 具有细胞穿透性、序列特异性和核酸水解性的抗体、其制备方法及包含所述抗体的药物组合物 |
| CN101402675B (zh) | 2008-11-28 | 2012-05-30 | 中国人民解放军第三军医大学第三附属医院 | 一种靶向抑制ανβ3阳性细胞增殖的环肽 |
| US20110053829A1 (en) | 2009-09-03 | 2011-03-03 | Curevac Gmbh | Disulfide-linked polyethyleneglycol/peptide conjugates for the transfection of nucleic acids |
| WO2011140151A1 (en) | 2010-05-04 | 2011-11-10 | Dyax Corp. | Antibodies against epidermal growth factor receptor (egfr) |
| GB201103631D0 (en) | 2011-03-03 | 2011-04-13 | Univ Leeds | Identification of candidate therapeutics |
| EP2694555B1 (en) | 2011-04-01 | 2019-07-10 | Yale University | Cell-penetrating anti-dna antibodies and uses thereof to inhibit dna repair |
| US9283272B2 (en) | 2012-03-30 | 2016-03-15 | The United States Of America As Represented By The Department Of Veterans Affairs | Targeting intracellular target-binding determinants with intracellular antibodies |
| WO2014042209A1 (ja) | 2012-09-14 | 2014-03-20 | 公益財団法人がん研究会 | ＥｐＣＡＭに結合するペプチド |
| US10011635B2 (en) | 2013-09-27 | 2018-07-03 | H. Lee Moffitt Cancer Center And Research Institute, Inc. | Cyclic peptide conjugates and methods of use |
| KR101602876B1 (ko) | 2014-07-22 | 2016-03-11 | 아주대학교산학협력단 | 완전한 이뮤노글로불린 형태의 세포질 침투능을 갖는 항체를 이용하여 세포내 활성화된 ras를 억제하는 방법 및 그의 이용 |
| KR101602870B1 (ko) | 2014-07-22 | 2016-03-21 | 아주대학교산학협력단 | 완전한 이뮤노글로불린 형태의 항체를 세포막을 투과하여 세포질에 위치시키는 방법 및 그의 이용 |
| WO2016013871A1 (ko) | 2014-07-22 | 2016-01-28 | 아주대학교산학협력단 | 완전한 이뮤노글로불린 형태의 세포질 침투능을 갖는 항체를 이용하여 세포내 활성화된 ras를 억제하는 방법 및 그의 이용 |
| JP6903587B2 (ja) | 2015-04-03 | 2021-07-14 | ユーリカ セラピューティックス， インコーポレイテッド | Ａｆｐペプチド／ｍｈｃ複合体を標的化する構築物およびその使用 |
| KR101790669B1 (ko) | 2015-10-14 | 2017-10-26 | 아주대학교산학협력단 | 개선된 분할 녹색 형광 단백질 상보 시스템 및 이의 용도 |
| US11155641B2 (en) | 2016-05-27 | 2021-10-26 | Orum Therapeutics Inc. | Cytosol-penetrating antibody and use thereof |
| KR101836392B1 (ko) | 2016-08-17 | 2018-03-08 | 한림대학교 산학협력단 | 사이클릭 펩타이드를 포함하는 백신 조성물, 사이클릭 펩타이드에 대한 항체 또는 이를 포함하는 항암 조성물 |
| KR102163305B1 (ko) | 2017-11-16 | 2020-10-08 | 오름테라퓨틱 주식회사 | 세포의 세포질에 침투하여 세포내 활성화된 Ras를 억제하는 항체 및 이의 용도 |
| WO2019244086A1 (en) | 2018-06-21 | 2019-12-26 | Orum Therapeutics Inc. | Cell/tissue-specific cell-penetrating antibodies |
-
2015
- 2015-07-21 KR KR1020150103163A patent/KR101602870B1/ko not_active Expired - Fee Related
- 2015-07-22 CN CN201580045139.0A patent/CN107001481A/zh active Pending
- 2015-07-22 EP EP15825418.5A patent/EP3173428B1/en active Active
- 2015-07-22 JP JP2017525495A patent/JP6595592B2/ja not_active Expired - Fee Related
- 2015-07-22 AU AU2015292955A patent/AU2015292955B2/en not_active Ceased
- 2015-07-22 BR BR112017001304-5A patent/BR112017001304A2/pt not_active Application Discontinuation
- 2015-07-22 RU RU2017103675A patent/RU2017103675A/ru not_active Application Discontinuation
- 2015-07-22 US US15/327,369 patent/US10844136B2/en not_active Expired - Fee Related
- 2015-07-22 CA CA2955272A patent/CA2955272A1/en not_active Abandoned
-
2017
- 2017-01-19 IL IL250203A patent/IL250203B/en not_active IP Right Cessation
- 2017-01-20 ZA ZA2017/00488A patent/ZA201700488B/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| US10844136B2 (en) | 2020-11-24 |
| KR101602870B1 (ko) | 2016-03-21 |
| AU2015292955A1 (en) | 2017-02-09 |
| EP3173428B1 (en) | 2020-02-19 |
| EP3173428A4 (en) | 2018-01-24 |
| CA2955272A1 (en) | 2016-01-28 |
| IL250203A0 (en) | 2017-03-30 |
| RU2017103675A (ru) | 2018-08-06 |
| IL250203B (en) | 2020-09-30 |
| AU2015292955B2 (en) | 2020-08-13 |
| EP3173428A1 (en) | 2017-05-31 |
| KR20160011598A (ko) | 2016-02-01 |
| JP6595592B2 (ja) | 2019-10-23 |
| BR112017001304A2 (pt) | 2018-01-30 |
| CN107001481A (zh) | 2017-08-01 |
| US20170218084A1 (en) | 2017-08-03 |
| JP2017529097A (ja) | 2017-10-05 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ZA201700488B (en) | Method for positioning, in cytoplasm, antibody having complete immunoglobulin form by penetrating antibody through cell membrane, and use for same | |
| IL320713A (en) | Antibodies, uses and methods | |
| ZA202105220B (en) | Cell penetrating antibodies | |
| DK3174874T3 (da) | Berberinsalte, ursodeoxycholsalte og kombinationer, fremgangsmåder til fremstilling og anvendelse deraf. | |
| SG11201706826VA (en) | Method for separating cells, and device therefor | |
| EP3130604A4 (en) | Anti-il-17 antibodies, method for producing same and method for using same | |
| EP3150692A4 (en) | Cell evaluation device, method, and program | |
| EP3173099A4 (en) | Method for suppressing ras activated in cell by using antibody having cytoplasm penetration capacity and complete immunoglobulin form, and use for same | |
| EP3150693A4 (en) | Cell determination device, method, and program | |
| EP3091786A4 (en) | Apparatus, method and system for cell selection | |
| EP3133865A4 (en) | Method, device and system for cell reselection | |
| EP3176277A4 (en) | Ferritic stainless steel material for fuel cell, and method for producing same | |
| EP3239691A4 (en) | Cell imaging device, cell imaging method, and sample cell | |
| EP3118750A4 (en) | Factor analysis device, factor analysis method, and factor analysis program | |
| IL252430A0 (en) | Antibodies, uses and methods | |
| SG11201701562WA (en) | Cell trapping method, method for producing specific cell-trapping device, and method for producing specific cell-containing solution | |
| EP3150694A4 (en) | Cell evaluation device, method, and program | |
| EP3220464A4 (en) | Cell structure, method for producing same, and fuel cell | |
| EP3107141A4 (en) | Microbial fuel cell, microbial fuel cell system, and method for using microbial fuel cell | |
| EP3226607A4 (en) | Method and apparatus for transmitting information in cell | |
| KR101687291B9 (ko) | 3차원 세포배양 시스템 및 이를 이용한 세포 배양 방법 | |
| EP3275993B8 (en) | Device for producing information for cell analysis, method for producing information for cell analysis, and program | |
| BR112016030851A2 (pt) | recipiente de separação de células, sistema de separação de células e método de separação de células | |
| SG11201700557RA (en) | Lipid membrane structure, lipid-membrane-structure-immobilization carrier, and method for fusing cells | |
| PL3102671T3 (pl) | Drożdże ekologiczne, sposób otrzymywania i zastosowania |